PPRS Research
PPRS RESEARCH is a strategic organization that assists small biotechs and larger biopharmaceutical companies throughout the drug development process. With a multi-specialist business model, PPRS aims to identify early-stage projects with strong potential, develop cross-border operations, strengthen expertise, and propose innovative development solutions. The company operates in various therapeutic areas including Neurosciences, Infectious Diseases, Immunology, Cardio-vascular Diseases, Orphan Drugs, and Pain. PPRS offers a broad range of services from early phase development support to clinical trial services and nonclinical consulting, and also develops innovative medical devices through its MDIS team. The company has a rich history of growth, investments, and strategic collaborations since its founding in 2010.
Industries
Nr. of Employees
small (1-50)
PPRS Research
Products
Automated sleep scoring and monitoring solution
Integrated system for ambulatory sleep monitoring and automated sleep-stage scoring intended for clinical research and diagnostic support.
Automated sleep scoring and monitoring solution
Integrated system for ambulatory sleep monitoring and automated sleep-stage scoring intended for clinical research and diagnostic support.
Services
End-to-end CMC support including formulation testing, raw material characterization, methods development/validation, CMO selection, clinical batch manufacturing oversight and regulatory dossier preparation.
Vendor selection and study management for preclinical programs including PD/PK, efficacy, mechanism-of-action and toxicology studies and regulatory strategy design.
Feasibility, study start-up, site selection and qualification, monitoring, study document development, IRB/EC submissions, and investigator meeting organization.
Hardware and software engineering, clinical validation, regulatory affairs support (CE marking / FDA submissions), and market analysis for medical device products, with specific experience in sleep monitoring solutions.
Support for development and deployment of smart data and AI strategies for biomedical signal analysis and product development.
End-to-end CMC support including formulation testing, raw material characterization, methods development/validation, CMO selection, clinical batch manufacturing oversight and regulatory dossier preparation.
Vendor selection and study management for preclinical programs including PD/PK, efficacy, mechanism-of-action and toxicology studies and regulatory strategy design.
Feasibility, study start-up, site selection and qualification, monitoring, study document development, IRB/EC submissions, and investigator meeting organization.
Hardware and software engineering, clinical validation, regulatory affairs support (CE marking / FDA submissions), and market analysis for medical device products, with specific experience in sleep monitoring solutions.
Support for development and deployment of smart data and AI strategies for biomedical signal analysis and product development.
Expertise Areas
- Clinical trial management
- CMC and formulation development
- Non-clinical development and toxicology
- Medical device research and development
Key Technologies
- Signal processing for physiological data
- Machine learning / AI for biomedical analytics
- Polysomnography and automated sleep scoring algorithms
- Pharmacokinetics / pharmacodynamics studies
News & Updates
The company was founded in 2010.
In 2011, the company had 5 employees.
By 2012, PPRS had 4 drug projects in development.
In 2013, the company was granted the status of 'Young Innovative Company'.
In 2014, PPRS established a US subsidiary in Boston, with 12 employees, and made direct investments in Minerva Neurosciences and V-Watch/Somno-Art.
In 2016, Somno-Art Solution was approved and market-ready, and phase II results for Minerva Neurosciences were successful.
The company was founded in 2010.
In 2011, the company had 5 employees.
By 2012, PPRS had 4 drug projects in development.
In 2013, the company was granted the status of 'Young Innovative Company'.
In 2014, PPRS established a US subsidiary in Boston, with 12 employees, and made direct investments in Minerva Neurosciences and V-Watch/Somno-Art.
In 2016, Somno-Art Solution was approved and market-ready, and phase II results for Minerva Neurosciences were successful.